TGTX

Business Context and Reporting Period

Company: Manhattan Pharmaceuticals, Inc. (Note: Metadata referenced "TG THERAPEUTICS, INC.", but the filing text identifies the registrant as Manhattan Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Stage: Development Stage Company. The company has generated no revenue to date and focuses on developing pharmaceutical treatments for underserved populations, primarily through a joint venture (Hedrin JV) for head lice treatment and a topical gel for psoriasis.

Key Financial Metrics

Debt Obligations: The company holds Secured 12% Notes Payable (net of discount) of approximately $1.58 million and an Exchange Obligation of approximately $3.95 million related to the Hedrin JV.

Material Changes vs. Prior Period

• Expense Reduction: Operating expenses decreased significantly compared to the prior year. Research and Development (R&D) expenses dropped 96% to $52,000 for the six months ended June 30, 2009, from $1.37 million in the prior period. General and Administrative (G&A) expenses decreased 43% to $983,000 from $1.72 million.
• Net Loss Improvement: Net loss for the six months ended June 30, 2009, was $2.15 million, a 28% decrease from the $3.00 million loss in the same period in 2008. This improvement was driven by reduced operational costs.
• Non-Cash Charges: The company recognized a non-cash charge of $816,667 due to the change in fair value of a derivative liability (warrants issued to Nordic Biotech), which increased the net loss. This item was not present in the prior year.
• Liquidity: Cash and cash equivalents increased from $106,023 at December 31, 2008, to $294,568 at June 30, 2009, primarily due to financing activities including proceeds from the Hedrin JV and Secured 12% Notes.

Guidance, Outlook, and Risks

Management Outlook: Management believes the company has sufficient capital to fund operations through the end of 2009. However, additional equity or debt financing, or positive cash flow from the Hedrin JV or licensing, will be required to sustain operations into 2010. The company expects to continue incurring net losses through at least June 30, 2010.

Going Concern: The filing explicitly states that the company's continued operations depend on raising additional funds. These matters raise substantial doubt about the company's ability to continue as a going concern.

Key Risks and Contingencies:

• Legal Proceedings: An arbitration award of approximately $646,000 (plus accrued interest) was rendered against the company by Swiss Pharma Contract LTD. The company lacks sufficient cash to satisfy this award and is in settlement discussions. A judgment confirming the award was presented to the New York Supreme Court in August 2009.
• Derivative Liability: Adoption of EITF 07-5 resulted in the reclassification of certain warrants to derivative liabilities, creating volatility in the income statement based on fair value changes.
• Product Development: The company terminated license agreements for Altoderm, Altolyn, and IGI (Topical PTH) in 2009 due to lack of funds or failed clinical results. Future success relies heavily on the Hedrin JV.

Investor Verification Checklist

• Going Concern Status: Verify the company's ability to secure financing before the end of 2009 to avoid insolvency.
• Swiss Pharma Arbitration: Monitor the status of the $646,000+ arbitration award and potential settlement terms, as the company cannot currently pay this in full.
• Derivative Liability Volatility: Assess the impact of the $838,889 derivative liability on future earnings, as fair value changes will directly affect net income.
• Hedrin JV Milestones: Confirm the progress of the Hedrin JV in obtaining FDA Premarket Approval (PMA) for the Class III medical device designation.
• Debt Covenants: Review the terms of the Secured 12% Notes, which are secured by nearly all company assets (excluding the Hedrin JV interest) and require monthly installments from restricted cash.